WallStSmart

China SXT Pharmaceuticals Inc (SXTC)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 206838% more annual revenue ($3.18B vs $1.54M). UTHR leads profitability with a 41.9% profit margin vs 0.0%. UTHR earns a higher WallStSmart Score of 67/100 (B-).

SXTC

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0

UTHR

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 9.0Value: 10.0Quality: 7.8
Piotroski: 5/9Altman Z: 7.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for SXTC.

UTHRUndervalued (+62.9%)

Margin of Safety

+62.9%

Fair Value

$1282.02

Current Price

$541.60

$740.42 discount

UndervaluedFair: $1282.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SXTC2 strengths · Avg: 9.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

EPS GrowthGrowth
42.6%8/10

Earnings expanding 42.6% YoY

UTHR4 strengths · Avg: 9.5/10
Profit MarginProfitability
41.9%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
45.0%10/10

Strong operational efficiency at 45.0%

Altman Z-ScoreHealth
7.3010/10

Safe zone — low bankruptcy risk

EPS GrowthGrowth
24.5%8/10

Earnings expanding 24.5% YoY

Areas to Watch

SXTC4 concerns · Avg: 2.5/10
Market CapQuality
$1.20M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-50.3%2/10

ROE of -50.3% — below average capital efficiency

Revenue GrowthGrowth
-24.5%2/10

Revenue declined 24.5%

UTHR1 concerns · Avg: 4.0/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : SXTC

The strongest argument for SXTC centers on Price/Book, EPS Growth.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.

Bear Case : SXTC

The primary concerns for SXTC are Market Cap, Profit Margin, Return on Equity.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio.

Key Dynamics to Monitor

SXTC profiles as a value stock while UTHR is a mature play — different risk/reward profiles.

SXTC carries more volatility with a beta of 1.74 — expect wider price swings.

UTHR is growing revenue faster at 7.4% — sustainability is the question.

UTHR generates stronger free cash flow (173M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (67/100 vs 41/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

China SXT Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China

China SXT Pharmaceuticals, Inc., a pharmaceutical company, is engaged in the research, development, manufacture, marketing and sale of Traditional Chinese Medicine Tablets (TCMP) in China. The company is headquartered in Taizhou, China.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?